LASIK world literature review: quality of life and patient satisfaction.
Kerry D Solomon, Luis E Fernández de Castro, Helga P Sandoval...
https://pubmed.ncbi.nlm.nih.gov/19344821/Actively Recruiting
Led by VIS, Inc. · Updated on 2024-09-05
75
Participants Needed
4
Research Sites
52 weeks
Total Duration
This research aims to evaluate the safety and effectiveness of the VIS Opti-K System in improving near vision temporarily by treating the non-dominant eye of adults with presbyopia who have low myopia, emmetropia, or low hyperopia. The study focuses on measuring uncorrected near visual acuity at 40cm and patients subjective satisfaction with their vision. It is a Phase III clinical trial led by VIS, Inc., targeting adults aged 40 years and older. Participants who agree to monovision will receive a single treatment using the VIS Optimal Keratoplasty Opti-K System on their non-dominant eye. The other eye will not receive treatment during this pivotal study. Eligible subjects may undergo one retreatment if necessary to assess the devices impact on near vision. During the trial, participants will attend follow-up visits where their near visual acuity and binocular vision will be measured at three months after treatment. They will also complete satisfaction questionnaires to report their experience. The study monitors visual outcomes and safety over the follow-up period, with participation lasting at least three months after the initial treatment.
CONDITIONS
Phase III Presbyopia Correction Using the VIS Opti-K™ System
K
Kristy Wort
G
George Aubrey
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
VIS, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | VIS Opti-K™ System (Laser Keratoplasty) | Conductive Keratoplasty (CK) |
|---|---|---|
| What is it? | A laser keratoplasty device procedure aiming to improve near vision in adults with presbyopia by reshaping the cornea using the Opti-K™ system. | A radiofrequency energy procedure (CK) approved to correct presbyopia and low-to-moderate hyperopia, changing the corneal shape to improve near vision. |
| Role in study | Investigational device tested for presbyopia correction in a single-arm clinical trial. | Current device procedure established in clinical practice and supported by FDA; not studied in this trial but matched to trial population and procedure intent. |
| Primary clinical use | Improvement of near vision for adults with presbyopia who meet defined visual acuity and refraction criteria. | Correction of presbyopia or low-to-moderate hyperopia by enhancing near vision without glasses in adults meeting similar eligibility. |
| How is it performed? | Laser energy is applied to the cornea in both eyes using the Opti-K™ device during an outpatient procedure. | A handheld probe delivers radiofrequency energy in a ring pattern, causing controlled corneal reshaping; performed as an outpatient device procedure. |
| Evidence status | Device effectiveness and safety not yet established in published literature; 3-month primary outcome is improvement in uncorrected near visual acuity. | Multiple published trials show CK improves near vision for presbyopia. U.S. clinical trial demonstrated significant improvements at 1 year, including patient satisfaction. |
| Important limitations | Long-term effects, durability of vision correction, safety, and patient satisfaction are not yet established. Outcomes are limited to 3 months at present. | Improvements in near vision may lessen over time. Some patients require retreatment due to regression. Procedural risk includes dry eye, temporary discomfort, and possible under- or over-correction. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single treatment with possible single retreatment
Participants receive the VIS Optimal Keratoplasty (Opti-K™) System treatment in the non-dominant eye, with a single retreatment if applicable.
1 to 2 visits depending on retreatment
Duration - Approximately 3 months
Participants are monitored after treatment to assess uncorrected near visual acuity and safety.
Multiple visits over 3 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Kerry D Solomon, Luis E Fernández de Castro, Helga P Sandoval...
https://pubmed.ncbi.nlm.nih.gov/19344821/Marguerite B McDonald, Peter S Hersh, Edward E Manche...
https://pubmed.ncbi.nlm.nih.gov/12414402/VIS, Inc.
Lead Sponsor